Digital Interventions to Increase HPV Vaccination Intentions Among Nigerian Caregivers
A Randomized Trial of Digital Interventions to Increase HPV Vaccination Intentions Among Nigerian Caregivers
1 other identifier
interventional
3,340
0 countries
N/A
Brief Summary
This study evaluates whether different types of digital health communication can increase parents' intention to vaccinate their daughters against human papillomavirus (HPV) in Nigeria. HPV vaccination is recommended for girls aged 9-14 years and helps prevent cervical cancer, yet vaccination rates remain low. Parents of eligible, unvaccinated girls will be randomly assigned to receive one of several types of digital content delivered online. These include: (1) a short chatbot conversation based on motivational interviewing principles, (2) an interactive game designed to help parents recognize and resist common forms of vaccine misinformation, (3) a set of short edutainment videos about HPV vaccination, (4) standard informational infographics about HPV vaccination from a national public health agency, or (5) unrelated health content about menstruation. The main outcome is parents' self-reported intention to vaccinate their daughter against HPV, measured immediately and one week after exposure to the assigned content. Additional outcomes include HPV-related knowledge, perceptions of vaccine safety, willingness to recommend the vaccine to others, and self-reported vaccine uptake at 1-week and 6 month follow-up. The results will help inform scalable communication strategies to improve HPV vaccination uptake in low- and middle-income settings.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started May 2026
Shorter than P25 for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 23, 2026
CompletedFirst Posted
Study publicly available on registry
March 27, 2026
CompletedStudy Start
First participant enrolled
May 18, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2026
May 20, 2026
May 1, 2026
8 months
March 23, 2026
May 18, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
HPV Vaccination Intention (1-Week Post-Intervention)
Parent's self-reported intention to vaccinate their selected daughter (aged 9-14 years) against HPV, measured on a 10-point numeric scale, where higher values indicate greater intention to vaccinate. If a participant has more than one eligible daughter, one daughter is randomly selected for all outcome questions.
1 week after exposure to the assigned intervention content
HPV Vaccination Intention (Immediately Post-Intervention)
Parent's self-reported intention to vaccinate their selected daughter against HPV, measured on a 10-point numeric scale.
Immediately Post-Intervention
Secondary Outcomes (12)
HPV Vaccination Intention (6 months post-intervention)
6 months post-intervention
Self-Reported HPV Vaccine Uptake
6 months post-intervention
Perceived Safety of the HPV Vaccine
1 week post-intervention, 6 months post-intervention
Likelihood of Recommending the HPV Vaccine to Other Parents
1 week post-intervention, 6 months post-intervention
Self-Reported Knowledge of the HPV Vaccine
1 week post-intervention, 6 months post-intervention
- +7 more secondary outcomes
Other Outcomes (1)
Engagement With Assigned Intervention Content
During intervention exposure
Study Arms (5)
Chatbot counseling arm
EXPERIMENTALA brief motivational-interviewing-style chatbot dialogue adapted from WHO vaccination counseling guidance
Misinformation-resistance pre-bunking inoculation arm
EXPERIMENTALA short interactive game (approximately 3-5 minutes) designed to build resistance to HPV vaccine misinformation
Short edutainment arm
EXPERIMENTAL5-6 brief edutainment videos (total viewing time approximately 10-15 minutes) providing HPV vaccine information tailored to the Nigerian context
Standard infographic control arm
ACTIVE COMPARATORExisting infographics on HPV vaccination from Nigeria's National Primary Health Care Development Agency (NPHCDA)
Unrelated content control arm
NO INTERVENTIONSeries of infographics on menstruation from Nigeria's Menstrual Health Advocacy Consortium
Interventions
A brief motivational-interviewing-style chatbot dialogue adapted from WHO vaccination counseling guidance
A short interactive game (approximately 3-5 minutes) designed to build resistance to HPV vaccine misinformation
5-6 brief edutainment videos (total viewing time approximately 10-15 minutes) providing HPV vaccine information tailored to the Nigerian context
Existing infographics on HPV vaccination from Nigeria's National Primary Health Care Development Agency (NPHCDA)
Eligibility Criteria
You may qualify if:
- Parent or primary caregiver of at least one girl aged 9-14 years
- Parent states "no" or "unsure" to question asking if eligible daughter has received any doses of the HPV vaccine
- Provides informed consent to participate
You may not qualify if:
- Parent or caregiver of a girl who has already received one or more doses of the HPV vaccine
- Does not meet age eligibility criteria for an eligible daughter
- Fails Attention Checks
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Pennsylvanialead
- World Bank Groupcollaborator
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 23, 2026
First Posted
March 27, 2026
Study Start
May 18, 2026
Primary Completion (Estimated)
December 31, 2026
Study Completion (Estimated)
December 31, 2026
Last Updated
May 20, 2026
Record last verified: 2026-05
Data Sharing
- IPD Sharing
- Will share
De-identified individual participant data underlying the primary and secondary outcome analyses will be shared. This includes randomized treatment assignment, baseline covariates, outcome measures related to HPV vaccination intention, knowledge, attitudes, and self-reported vaccine uptake, as well as basic demographic variables. Data will be de-identified prior to sharing and will not include direct identifiers or information that could reasonably be used to re-identify participants.